An Open-label Pilot Study to Determine the Safety and Efficacy of Fixed-dose Glecaprevir and Pibrentasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 Sep 2018 Status changed from not yet recruiting to recruiting.
- 10 Sep 2018 Planned initiation date changed from 25 Aug 2018 to 1 Nov 2018.
- 21 Aug 2018 New trial record